Supports innovative research exploring novel approaches for targeting Neuro-restoration, remyelination and / or neuroprotection in the Central Nervous System, thus laying the foundation for future drug discovery efforts. This grant is designed to accelerate the trajectory of converting promising scientific discoveries into therapeutics that will benefit Advanced (progressive) MS patients. Grants will be given to enable novel concepts in MS drug discovery, preclinical development, and translational CNS science. Feasibility and proof-of-concept research plans must focus on the key aspects that drive risk in moving those concepts forward.
Some example areas of interest include, but are not limited to:
- Target validation studies in state-of-the-art patient-derived preclinical models
- Development of novel targeting approaches and new therapeutic modalities
A key feature of the Therapeutic Innovation Grant is the unprecedented level of support provided to the selected projects. The Start2Cure Foundation’s scientific team and network of advisors have extensive pharmaceutical industry experience that enables them to give expert scientific and technical guidance in the drug development process with the ultimate goal of bringing new drug candidates into the clinic. .
For who: academic investigators or teams as well as early stage biotech companies*
Submission deadline step 1: First of September.
Duration project: 1 – 4 years.
Grant amount: Maximum of €500.000,- per year.
* early stage biotech companies will be provided with soft loans under standard conditions